Evidence map›Paper›PMID 19413885›Full record

ArticleJournal of cellular and molecular medicine2009

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway.

Jun Cai, Fang-Fang Yi, Zhou-Yan Bian, Di-Fei Shen, Long Yang, Ling Yan, Qi-Zhu Tang, Xin-Chun Yang, Hongliang Li

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Impact ofNutrients · 2020
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Crocetin: A Systematic Review.Frontiers in pharmacology · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Immunoregulatory and anti-inflammatory properties ofIranian journal of basic medical sciences · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jun CaiCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Fang-Fang Yi
Zhou-Yan Bian
Di-Fei Shen
Long Yang
Ling Yan
Qi-Zhu Tang
Xin-Chun Yang
Hongliang Li
Wuhan University · CNCapital Medical University · CNHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress plays a critical role in the progression of pathological cardiac hypertrophy and heart failure. Because crocetin represses oxidative stress in vitro and in vivo, we have suggested that crocetin would repress cardiac hypertrophy by targeting oxidative stress-dependent signalling. We tested this hypothesis using primary cultured cardiac myocytes and fibroblasts and one well-established animal model of cardiac hypertrophy. The results showed that crocetin (1-10 microM) dose-dependently blocked cardiac hypertrophy induced by angiogensin II (Ang II; 1 microM) in vitro. Our data further revealed that crocetin (50 mg/kg/day) both prevented and reversed cardiac hypertrophy induced by aortic banding (AB), as assessed by heart weight/body weight and lung weight/body weight ratios, echocardio-graphic parameters and gene expression of hypertrophic markers. The inhibitory effect of crocetin on cardiac hypertrophy is mediated by blocking the reactive oxygen species (ROS)-dependent mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase-1/2 (MEK/ERK1/2) pathway and GATA binding protein 4 (GATA-4) activation. Further investigation demonstrated that crocetin inhibited inflammation by blocking nuclear factor kappa B (NF-kappaB) signalling and attenuated fibrosis and collagen synthesis by abrogating MEK-ERK1/2 signalling. Overall, our results indicate that crocetin, which is a potentially safe and inexpensive therapy for clinical use, has protective potential in targeting cardiac hypertrophy and fibrosis by suppression of ROS-dependent signalling pathways.

Indexed as

AnimalsAnimals, NewbornAntioxidantsCardiomegalyCarotenoidsCells, CulturedCell SizeCollagenExtracellular Signal-Regulated MAP KinasesFibroblastsGATA4 Transcription FactorMaleMAP Kinase Signaling SystemMiceMice, Inbred C57BLMyocytes, CardiacAntioxidantsCarotenoidsCollagenExtracellular Signal-Regulated MAP KinasesGATA4 Transcription FactorNF-kappa BReactive Oxygen Speciestrans-sodium crocetinateVitamin A

Identifiers

PMID19413885
PMCPMC3823407
OpenAlexW2100809320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.